Uijterwijk Bas A, Lemmers Daniël H, Fusai Giuseppe Kito, Groot Koerkamp Bas, Koek Sharnice, Zerbi Alessandro, Sparrelid Ernesto, Boggi Ugo, Luyer Misha, Ielpo Benedetto, Salvia Roberto, Goh Brian K P, Kazemier Geert, Björnsson Bergthor, Serradilla-Martín Mario, Mazzola Michele, Mavroeidis Vasileios K, Sánchez-Cabús Santiago, Pessaux Patrick, White Steven, Alseidi Adnan, Valle Raffaele Dalla, Korkolis Dimitris, Bolm Louisa R, Soonawalla Zahir, Roberts Keith J, Vladimirov Miljana, Mazzotta Alessandro, Kleeff Jorg, Suarez Muñoz Miguel Angel, Besselink Marc G, Hilal Mohammed Abu
Department of Surgery, Fondazione Poliambulanza, 25124 Brescia, Italy.
Department of Surgery, Amsterdam UMC, University of Amsterdam, 1012 Amsterdam, The Netherlands.
Cancers (Basel). 2024 Feb 23;16(5):899. doi: 10.3390/cancers16050899.
This international multicenter cohort study included 30 centers. Patients with duodenal adenocarcinoma (DAC), intestinal-type (AmpIT) and pancreatobiliary-type (AmpPB) ampullary adenocarcinoma, distal cholangiocarcinoma (dCCA), and pancreatic ductal adenocarcinoma (PDAC) were included. The primary outcome was 30-day or in-hospital mortality, and secondary outcomes were major morbidity (Clavien-Dindo 3b≥), clinically relevant post-operative pancreatic fistula (CR-POPF), and length of hospital stay (LOS). Results: Overall, 3622 patients were included in the study (370 DAC, 811 AmpIT, 895 AmpPB, 1083 dCCA, and 463 PDAC). Mortality rates were comparable between DAC, AmpIT, AmpPB, and dCCA (ranging from 3.7% to 5.9%), while lower for PDAC (1.5%, = 0.013). Major morbidity rate was the lowest in PDAC (4.4%) and the highest for DAC (19.9%, < 0.001). The highest rates of CR-POPF were observed in DAC (27.3%), AmpIT (25.5%), and dCCA (27.6%), which were significantly higher compared to AmpPB (18.5%, = 0.001) and PDAC (8.3%, < 0.001). The shortest LOS was found in PDAC (11 d vs. 14-15 d, < 0.001). Discussion: In conclusion, this study shows significant variations in perioperative mortality, post-operative complications, and hospital stay among different periampullary cancers, and between the ampullary subtypes. Further research should assess the biological characteristics and tissue reactions associated with each type of periampullary cancer, including subtypes, in order to improve patient management and personalized treatment.
这项国际多中心队列研究纳入了30个中心。纳入了十二指肠腺癌(DAC)、肠型(AmpIT)和胰胆管型(AmpPB)壶腹腺癌、远端胆管癌(dCCA)以及胰腺导管腺癌(PDAC)患者。主要结局为30天或住院死亡率,次要结局为严重并发症(Clavien-Dindo 3b级及以上)、临床相关术后胰瘘(CR-POPF)以及住院时间(LOS)。结果:总体而言,3622例患者纳入研究(370例DAC、811例AmpIT、895例AmpPB、1083例dCCA和463例PDAC)。DAC、AmpIT、AmpPB和dCCA的死亡率相当(3.7%至5.9%),而PDAC的死亡率较低(1.5%,P = 0.013)。严重并发症发生率在PDAC中最低(4.4%),在DAC中最高(19.9%,P < 0.001)。CR-POPF发生率在DAC中最高(27.3%)、AmpIT中为(25.5%)和dCCA中为(27.6%),与AmpPB(18.5%,P = 0.001)和PDAC(8.3%,P < 0.001)相比显著更高。PDAC的住院时间最短(11天 vs. 14 - 15天,P < 0.001)。讨论:总之,本研究表明不同壶腹周围癌以及壶腹亚型之间围手术期死亡率、术后并发症和住院时间存在显著差异。进一步研究应评估与每种壶腹周围癌类型(包括亚型)相关的生物学特征和组织反应,以改善患者管理和个性化治疗。